Pilot Study of the Effect of Methyl B12 Treatment on Behavioral and Biomarker Measures in Children with Autism
Authors:
- 1 May 2010
- journal article
- research article
- Published by SAGE Publications in The Journal of Alternative and Complementary Medicine
- Vol. 16 (5) , 555-560
Abstract
The study objectives were to determine whether methyl B12 treatment improves behavioral measures in children with autism and whether improvement is associated with increased plasma concentrations of glutathione (GSH) and an increased redox ratio of reduced glutathione to oxidized glutathione (GSH/GSSG), both of which have been previously identified to be low in children with autism. This was a 12-week, double-blind, placebo-controlled, cross-over clinical trial of injectable methyl B12. Following this 12-week study, subjects were given the option of entering a 6-month open-label trial of methyl B12. All procedures took place at the UC Davis M.I.N.D. Institute. Subjects were 3 to 8 years old with autism. All subjects received 6 weeks of placebo and 6 weeks of methyl B12 at a dose of 64.5 mcg/kg every three days administered subcutaneously into the buttocks. Blood for GSH analysis and behavioral assessments were obtained at baseline, week 6, and week 12. Thirty (30) subjects completed the 12-week, double-blind study and 22 subjects completed the 6-month extension study. No statistically significant mean differences in behavior tests or in glutathione status were identified between active and placebo groups. Nine (9) subjects (30%) demonstrated clinically significant improvement on the Clinical Global Impression Scale and at least two additional behavioral measures. More notably, these responders exhibited significantly increased plasma concentrations of GSH and GSH/GSSG. Comparison of the overall means between groups suggests that methyl B12 is ineffective in treating behavioral symptoms of autism. However, detailed data analysis suggests that methyl B12 may alleviate symptoms of autism in a subgroup of children, possibly by reducing oxidative stress. An increase in glutathione redox status (GSH/GSSG) may provide a biomarker for treatment response to methyl B12. Additional research is needed to delineate a subgroup of potential responders and ascertain a biomarker for response to methyl B12.Keywords
This publication has 18 references indexed in Scilit:
- A public health collaboration for the surveillance of autism spectrum disordersPaediatric and Perinatal Epidemiology, 2007
- Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autismThe American Journal of Clinical Nutrition, 2004
- Age at First Measles-Mumps-Rubella Vaccination in Children With Autism and School-Matched Control Subjects: A Population-Based Study in Metropolitan AtlantaPediatrics, 2004
- Folate and homocysteine metabolism in neural plasticity and neurodegenerative disordersTrends in Neurosciences, 2003
- The Neurobiological Context of AutismMolecular Neurobiology, 2003
- Is medical genetics neglecting epigenetics?Genetics in Medicine, 2002
- Prevalence of Autism in a United States Population: The Brick Township, New Jersey, InvestigationPediatrics, 2001
- Impaired Homocysteine Metabolism and Atherothrombotic DiseaseLaboratory Investigation, 2001
- The environment as an etiologic factor in autism: a new direction for research.Environmental Health Perspectives, 2000
- A Community Survey of Infantile AutismJournal of the American Academy of Child Psychiatry, 1986